Is AstraZeneca plc or GlaxoSmithKline plc the best Black Friday buy?

Will AstraZeneca plc (LON: AZN) or GlaxoSmithKline plc (LON: GSK) soar over the medium-to-long term?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The healthcare sector is likely to become increasingly popular over the coming months. Why? The global economy faces a degree of risk that’s exceptionally high with Brexit, a new US presidency and a continued slowdown in China likely to have at least some negative impact on growth rates. As such, healthcare’s low positive correlation with the wider economy is likely to prove popular among investors.

Within the healthcare space, AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) offer remarkably different outlooks. In AstraZeneca’s case, it’s a company in the midst of a hugely challenging period. It has faced the loss of patents on key, blockbuster drugs in recent years and has struggled to replace them. As a result, AstraZeneca’s earnings have fallen by 41% in the last four years. They’re due to decline by an additional 9% over the next 24 months, which may cause some investors to avoid AstraZeneca at the present time.

However, the company’s earnings fall doesn’t paint the full picture. AstraZeneca is in the process of rapidly improving its pipeline through a major acquisition programme. It’s using its strong cash flow and modestly leveraged balance sheet to build a pipeline that has the potential to deliver improved financial performance over the long run. And with its shares trading on a price-to-earnings (P/E) ratio of just 12.7, it has a sufficiently wide margin of safety to merit investment.

A better buy?

This contrasts with GlaxoSmithKline. While it has endured a difficult period thanks to some loss of patents and bribery allegations in recent years, GlaxoSmithKline offers a relatively robust near-term outlook. It’s due to record a rise in earnings of 31% this year, followed by gains of 10% next year. As such, it could outperform AstraZeneca in the near term since its P/E ratio of 15.4 equates to a price-to-earnings growth (PEG) ratio of 1.5 when combined with its growth outlook.

GlaxoSmithKline’s business model also offers greater resilience than that of AstraZeneca. While the patent cycle has a huge impact on GlaxoSmithKline’s earnings, this is negated somewhat by its consumer goods division. Not only does this provide a degree of balance to the business, it also offers significant growth prospects in both the developed and developing world.

In terms of its income potential, GlaxoSmithKline has a yield of 5.2% from a dividend covered 1.2 times by profit. This compares to AstraZeneca’s yield of 5.2%, with its dividends being covered 1.5 times by profit. Both companies have the potential to raise dividends in the long run, although near-term rises may be lacking due to AstraZeneca’s lack of earnings growth and GlaxoSmithKline’s desire to boost its dividend coverage ratio. But both stocks offer relatively reliable and consistent income appeal.

However, with GlaxoSmithKline having a more diversified business model and superior earnings growth prospects, it’s the better buy of the two stocks at the present time. Both companies could benefit from rising uncertainty in the global economic outlook, but GlaxoSmithKline looks set to be the biggest beneficiary thanks to its higher level of stability.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »